SEC Comment Letter for GT Biopharma, Inc. (GTBP) (CIK 0000109657) (GTBP) — Feb 28, 2019
GT Biopharma, Inc. (GTBP) (CIK 0000109657)
Date: Feb. 28, 2019 · CIK: 0000109657 · Accession: 0000000000-19-003434
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-229667
Letter
February 26, 2019 Raymond Urbanski, M.D., Ph.D. Chief Executive Officer and Chairman of the Board GT Biopharma, Inc. 310 N. Westlake Blvd Suite 206 Westlake Village, CA 91362 Re:GT Biopharma, Inc. Registration Statement on Form S-3 Filed February 14, 2019 File No. 333-229667 Dear Dr. Urbanski: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Gary R. Henrie, Esq.
Show Raw Text
February 26, 2019
Raymond Urbanski, M.D., Ph.D.
Chief Executive Officer and Chairman of the Board
GT Biopharma, Inc.
310 N. Westlake Blvd
Suite 206
Westlake Village, CA 91362
Re:GT Biopharma, Inc.
Registration Statement on Form S-3
Filed February 14, 2019
File No. 333-229667
Dear Dr. Urbanski:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Gary R. Henrie, Esq.